BYOOVIZ

PeakmAb

ranibizumab-nuna

Samsung Bioepis
BLAINJECTIONINJECTABLE
Approved
Sep 2021
Lifecycle
Peak
Competitive Pressure
30/100

Mechanism of Action

Vascular Endothelial Growth Factor Inhibitors

Pharmacologic Class:

Vascular Endothelial Growth Factor Inhibitor

Indications (1)

Macular Degeneration
Company
Samsung Bioepis
Samsung Bioepis
Korea - Incheon
External Resources
DailyMed
Full prescribing information
FDA Drugs@FDA
FDA approval history
RxNorm
Drug nomenclature & identifiers